What is the causative agent of possible transfusion‑related pneumonia in a 64‑year‑old female with myelodysplastic syndrome in the intensive care unit?

Transfusion-Related Pneumonia: Causative Agents in ICU MDS Patient

In a 64-year-old female with MDS in the ICU, transfusion-related pneumonia is most likely caused by Gram-negative bacteria (particularly Pseudomonas, Enterobacter, and Klebsiella species), though you must also consider direct transfusion-transmitted bacterial contamination (especially Klebsiella pneumoniae in platelet products) and viral pathogens.

Primary Causative Agents to Consider

Gram-Negative Bacteria (Most Common)

The predominant pathogens in immunocompromised hematologic malignancy patients with pneumonia are Gram-negative organisms 1. In MDS patients specifically:

• Pseudomonas species (most frequent)
• Enterobacter species
• Klebsiella species
• Morganella morganii (emerging pathogen in functionally neutropenic patients) 2

These organisms account for the majority of nosocomial pneumonias in this population 1.

Direct Transfusion-Transmitted Bacterial Infection

Critically important in your differential: Platelet transfusions can directly transmit bacteria, with Klebsiella pneumoniae being a documented culprit causing fulminant sepsis within 15 minutes of transfusion initiation 3. This presents with:

• Rapid onset (minutes to hours after transfusion)
• Tachycardia and oxygen desaturation
• Rapid progression to septic shock

Viral Pathogens

Current ICU guidelines recommend testing for viral causes in suspected pneumonia 4. In MDS patients, consider:

• Cytomegalovirus (CMV) - documented in 6 of 30 cases in one series 1
• Influenza
• Respiratory syncytial virus
• SARS-CoV-2
• Adenovirus

Testing approach: Use viral NAAT panels on deep tracheal aspirates or bronchoalveolar lavage, as upper respiratory sampling may miss pathogens 4.

Secondary Pathogens

Gram-Positive Bacteria (Less Common)

• Staphylococcus species
• Streptococcus species

Fungal Pathogens

In MDS patients with prior chemotherapy or corticosteroid use:

• Candida species (8 of 30 cases) 1
• Aspergillus species (3 of 30 cases) 1

Critical caveat: Galactomannan testing can yield false-positives, leading to unnecessary antifungal therapy 5. Confirm with additional diagnostic methods.

Risk Factors Amplifying Infection Risk

Your 64-year-old MDS patient has multiple compounding risks:

• Functional neutropenia from MDS itself 2
• Transfusion-associated immunomodulation: Transfusion independently increases VAP risk (OR 1.89; 95% CI 1.33-2.68) 6, with even stronger association for late-onset VAP (OR 2.16) showing dose-response relationship 6
• ICU-specific factors: Continuous sedation (OR 1.43), type of nutritional support 6

Diagnostic Algorithm

1. Immediate blood cultures (three bottles: two aerobic, one anaerobic) - do not delay antimicrobials >45 minutes 4

2. Deep respiratory sampling (tracheal aspirate or BAL):

   • Bacterial stains and culture
   • Viral NAAT panel 4
   • Fungal studies if immunosuppressed

3. Transfusion investigation if temporal relationship exists:

   • Culture remaining blood product
   • Compare bacterial strains if positive

4. Consider atypical pathogens: Include Legionella, Stenotrophomonas maltophilia (can cause rapidly progressive hemorrhagic pneumonia in post-transplant MDS) 7, and Morganella morganii 2

Critical Pitfalls to Avoid

• Don't assume typical radiographic findings: Morganella morganii pneumonia can occur without organized consolidations 2
• Don't rely solely on galactomannan: False-positives occur; use multidisciplinary interpretation 5
• Don't overlook transfusion timing: Bacterial contamination presents within minutes to hours 3
• Don't forget polymicrobial infection: Multiple pathogens are common in this population 1

Prognosis Context

Mortality in MDS patients with nosocomial pneumonia in ICU settings is substantial (87% in one series) 1, emphasizing the need for rapid, broad-spectrum empiric coverage with early pathogen-directed de-escalation once cultures return.